ストックスクリーナーアプリを入手
5.26
0.00%
0.00
前日終値:
$5.26
開ける：
$5.33
24時間の取引高:
392.17K
Relative Volume:
2.12
時価総額：
$123.38M
収益：
$7.94M
当期純損益:
$-21.13M
株価収益率:
-4.8623
EPS:
-1.0818
ネットキャッシュフロー:
$-16.17M
1週間 パフォーマンス:
-10.24%
1か月 パフォーマンス:
+19.27%
6か月 パフォーマンス:
+8.45%
1年 パフォーマンス:
-16.84%
1日の値動き範囲:
$4.99
$5.635
1週間の範囲:
$4.99
$5.965
52週間の値動き範囲:
$3.7101
$7.75
Coya Therapeutics Inc Stock (COYA) Company Profile
名前
Coya Therapeutics Inc
セクター
電話
650.739.3939
住所
12645 MEMORIAL DR., SUITE F1 #305, HOUSTON
Compare COYA vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
COYA
Coya Therapeutics Inc
|
5.26 | 123.38M | 7.94M | -21.13M | -16.17M | -1.0818 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Coya Therapeutics Inc Stock (COYA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-09 | 開始されました | Lake Street | Buy |
| 2024-12-04 | 開始されました | D. Boral Capital | Buy |
Coya Therapeutics Inc (COYA) 最新ニュース
Discipline and Rules-Based Execution in COYA Response - Stock Traders Daily
Coya Therapeutics to Host Virtual Webinar on the Intersection of Repetitive Head Trauma, Brain Inflammation and Neurodegenerative Disease - AOL.com
COYA Q1 2026 Earnings: Narrower-Than-Expected Loss as Pipeline AdvancesProfitability Analysis - dars.gov.et
Is Coya Therapeutics, Inc. (COYA) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Behavioral Patterns of COYA and Institutional Flows - Stock Traders Daily
Coya Therapeutics, Inc. Actuals & Estimates (NASDAQ:COYA) - TradingView
Coya Therapeutics, Inc. Actuals & Estimates (BOATS:COYA) - TradingView
Coya Therapeutics Price Target Maintained With a $14.00/Share by Chardan Capital - Moomoo
H.C. Wainwright Remains a Buy on Coya Therapeutics, Inc. (COYA) - The Globe and Mail
Coya Therapeutics, Inc. Reports 2026 Annual Meeting Results and Company Information (NASDAQ: COYA) - Minichart
Coya Therapeutics Shareholders Back Board, Auditor at Meeting - TipRanks
Coya Therapeutics (NASDAQ: COYA) shareholders back board nominees and 2026 auditor - Stock Titan
COYA Forecast — Price Target — Prediction for 2027 - TradingView
H.C. Wainwright Maintains Coya Therapeutics(COYA.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Coya Therapeutics (COYA) Investor update Summary - Quartr
Number of shareholders of Coya Therapeutics, Inc. – NASDAQ:COYA - TradingView
Exosomes Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Innovex Therapeutics, Coya Therapeutics, EV Therapeutics, Endosome Therapy StemXO - Barchart.com
COYA Technical Analysis & Stock Price Forecast - Intellectia AI
Coya Therapeutics to Present ALSTARS Trial Design at the ENCALS 2026 Meeting - BioSpace
Coya Therapeutics Inc (COYA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Coya Therapeutics Inc (COYA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Coya Therapeutics Inc (COYA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Coya Therapeutics Inc (COYA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Coya Therapeutics Inc (COYA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Coya Therapeutics Inc (COYA) Institutional Confidence - TradingKey
Coya Therapeutics Inc (COYA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Coya Therapeutics Inc (COYA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Coya Therapeutics Inc (COYA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
COYA Maintains Buy Rating by Chardan Capital -- Price Target at $14 - GuruFocus
Coya Therapeutics (COYA) Gains 2.16% as Stock Nears Key Resistance ZoneDip Buy Trade - newsline.com
Oruka Therapeutics, Inc. (ORKA) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Coya Therapeutics Is Maintained at Buy by Chardan Capital - Moomoo
Coya Therapeutics CEO on ALS urgency and fast-tracking COYA 302 for patient impact - Yahoo Finance
Coya Therapeutics begins extension phase of ALSTARS trial for COYA 302 - MSN
Coya Therapeutics Announces the First Cohort of Patients in the ALSTARS Trial Have Begun the Blinded Active-Treatment Extension Phase - BioSpace
COYA Q1 2026 Earnings: EPS Surprises Wall Street with Narrower Loss, Stock DeclinesAnnual Financial Report - newsline.com
COYA Q1 2026 Earnings: Narrower-than-Expected Loss Amid Pre-Clinical DevelopmentSubscription Growth Report - dars.gov.et
This Onto Innovation Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
Roth MKM Initiates Coya Therapeutics(COYA.US) With Buy Rating, Announces Target Price $12 - Moomoo
Roth/MKM initiates Coya Therapeutics stock with buy rating By Investing.com - Investing.com South Africa
Roth/MKM initiates Coya Therapeutics stock with buy rating - Investing.com
Lake Street Keeps Their Buy Rating on Monopar Therapeutics Inc (MNPR) - The Globe and Mail
Coya Therapeutics (COYA) Surges 1.87% as Shares Approach Resistance ZoneStock Picks - newsline.com
COYACoya Therapeutics Inc Options - Finviz
Coya Therapeutics to Present ALSTARS Trial Design at the 5th ALS Drug Development Summit - BioSpace
COYA Q1 2026 Earnings: EPS Beat Provides Silver Lining as Revenue Remains AbsentEarnings Expansion Phase - The Legal Advocate
COYA Q1 2026 Earnings: Narrower-than-Expected Loss as Biotech Advances PipelineQuarterly Earnings - The Legal Advocate
COYA Q1 2026 Earnings: Narrowed Loss Beats Estimates, Stock Rises on Efficiency GainsGuidance vs Actual - The Legal Advocate
Coya 302 gets fast-track designation for ALS treatment - Healio
COYA | Coya Therapeutics, Inc. Common Executive Compensation - Quiver Quantitative
Coya Therapeutics secures FDA fast track status for COYA 302 - Yahoo Finance
Coya Therapeutics Inc (COYA) 財務データ
収益
当期純利益
現金流量
EPS
2.64%
大文字化:
|
ボリューム (24 時間):